Recombinant Human LRIG1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01725P-100UG

Human LRIG1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human LRIG1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01725P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human LRIG1 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ala35-Ser779. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q96JA1 |
Target Symbol | LRIG1 |
Synonyms | LIG-1; LIG1; LRIG1; D6Bwg0781e; Img |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Ala35-Ser779 |
Mol. Weight | The protein has a predicted MW of 83 kDa. Due to glycosylation, the protein migrates to 85-105 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human LRIG1, His Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone. |